-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Issuer symbol
-
VRTX
-
Transactions as of
-
03 Dec 2025
-
Transactions value $
-
-$23,131,913
-
Form type
-
4
-
Filing time
-
05 Dec 2025, 16:10:39 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| LEIDEN JEFFREY M |
Executive Chairman, Director |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
05 Dec 2025 |
0001242825 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$5.52M |
+63.8K |
+265.47% |
$86.52 |
87.8K |
03 Dec 2025 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
-$1.97M |
-4.47K |
-5.09% |
$440.40 |
83.3K |
03 Dec 2025 |
Direct |
F1, F2, F3 |
| transaction |
VRTX |
Common Stock |
Sale |
-$582K |
-1.32K |
-1.58% |
$441.26 |
82K |
03 Dec 2025 |
Direct |
F1, F2, F4 |
| transaction |
VRTX |
Common Stock |
Sale |
-$1.09M |
-2.47K |
-3.01% |
$443.21 |
79.5K |
03 Dec 2025 |
Direct |
F1, F2, F5 |
| transaction |
VRTX |
Common Stock |
Sale |
-$1.93M |
-4.35K |
-5.47% |
$444.36 |
75.2K |
03 Dec 2025 |
Direct |
F1, F2, F6 |
| transaction |
VRTX |
Common Stock |
Sale |
-$3.52M |
-7.9K |
-10.5% |
$445.56 |
67.3K |
03 Dec 2025 |
Direct |
F1, F2, F7 |
| transaction |
VRTX |
Common Stock |
Sale |
-$515K |
-1.15K |
-1.71% |
$447.05 |
66.1K |
03 Dec 2025 |
Direct |
F1, F2, F8 |
| transaction |
VRTX |
Common Stock |
Sale |
-$1.04M |
-2.32K |
-3.51% |
$448.78 |
63.8K |
03 Dec 2025 |
Direct |
F1, F2, F9 |
| transaction |
VRTX |
Common Stock |
Sale |
-$2.65M |
-5.88K |
-9.21% |
$449.84 |
57.9K |
03 Dec 2025 |
Direct |
F1, F2, F10 |
| transaction |
VRTX |
Common Stock |
Sale |
-$2.62M |
-5.81K |
-10.02% |
$451.20 |
52.1K |
03 Dec 2025 |
Direct |
F1, F2, F11 |
| transaction |
VRTX |
Common Stock |
Sale |
-$7.09M |
-15.7K |
-30.08% |
$452.20 |
36.5K |
03 Dec 2025 |
Direct |
F1, F2, F12 |
| transaction |
VRTX |
Common Stock |
Sale |
-$4.7M |
-10.4K |
-28.42% |
$453.34 |
26.1K |
03 Dec 2025 |
Direct |
F1, F2, F13 |
| transaction |
VRTX |
Common Stock |
Sale |
-$942K |
-2.07K |
-7.93% |
$455.22 |
24K |
03 Dec 2025 |
Direct |
F1, F2, F14 |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$91.10 |
+1 |
+0% |
$91.05 |
24K |
04 Dec 2025 |
Direct |
|
| holding |
VRTX |
Common Stock |
|
|
|
|
|
440 |
03 Dec 2025 |
401(k) |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-63.8K |
-100% |
$0.00 |
0 |
03 Dec 2025 |
Common Stock |
63.8K |
$86.52 |
Direct |
F15 |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-1 |
-100% |
$0.00 |
0 |
04 Dec 2025 |
Common Stock |
1 |
$91.05 |
Direct |
F15 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: